Histone deacetylase inhibitors (HDAC) are chemical compounds that inhibit the activity of HDAC enzymes. They help the body's immune cells to recognize and attack tumor cells. HDAC inhibitors are a new class of anti-cancer agents and are widely used in the diagnosis, treatment, and prognosis of cancer. They are used as mood stabilizers and anti-epileptics in psychiatry and neurology. They are considered a treatment option for hematological malignancies and play an important role in epigenetic or non-epigenetic regulation. There are about 18 known human HDACs, and based on their structures, they are classified into four classes.
MARKET SCOPE
The "Global HDAC Inhibitor Market Analysis to 2028" is a specialized and in-depth study of the healthcare industry with a special focus on the global market trend analysis. The report aims to provide an overview of the HDAC inhibitor market with detailed market segmentation by class, application, end user, and geography. The report provides key statistics on the market status of the leading HDAC inhibitor market players and offers key trends and opportunities in the market.
MARKET SEGMENTATION
-Based on class, the global HDAC inhibitor market is segmented into class I HDACs, class II HDACs, class III HDACs and class IV HDACs.
-On the basis of application, the market is bifurcated into oncology, neurology and others.
-On the basis of end-users, the market is bifurcated into hospitals, oncology clinics and others.
MARKET DYNAMICS
Drivers
-The increasing prevalence of cancer and various chronic diseases, high unmet needs in the treatment landscape, and rising demand for histone deacetylase inhibitors drive the HDAC inhibitor market.
-Rapid technological advancements and increasing R&D activities for cancer fuel market growth.
-Growing collaborations and investments in manufacturing and the growing need for innovative medications and improved therapies for cancer treatment boost market growth.
Restraints
-The unfavorable reimbursement policies.
-Lack of skilled professionals in developing economies.
REGIONAL FRAMEWORK
The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides an overview and forecast of the global market based on various segments. It also provides market size and forecast estimates from the year 2019 to 2028 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), the Middle East and Africa (MEA), and South America. The HDAC inhibitor market by each region is later sub-segmented by respective countries and segments. The report covers the analysis and forecast of 18 countries globally along with the current trend and opportunities prevailing in the region.
The report analyzes factors affecting the market from both demand and supply side and further evaluates market dynamics affecting the market during the forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA, and South America after evaluating political, economic, social and technological factors affecting the HDAC inhibitor market in these regions.
IMPACT OF COVID-19 ON HDAC INHIBITOR MARKET
COVID-19 first began in Wuhan (China) during December 2019, and since then, it has spread at a fast pace across the globe. The US, India, Brazil, Russia, France, UK, Turkey, Italy, and Spain are some of the worst affected countries in terms of confirmed cases and reported deaths. The HDAC inhibitors are utilized by diabetic and kidney patients to fight the disease-causing cells. The histone deacetylase (HDAC) inhibitor valproic acid, which has been available for the therapy of epilepsy for many years, is a drug that could be repurposed for patients suffering from Covid-19 infection to avoid acute respiratory syndrome. The valproic acid helps the person who is infected to decrease the respiratory distress syndrome along with other organ damage, reducing hospitalization. HDAC provides drugs that are used in treating the infectious virus. Hence, the demand has surged, resulting in the growth of the market. Early intervention with HDAC inhibitors addressing the secondary consequences of SARS-CoV-2 infection will help reduce complications and mortality and provide a better quality of life for COVID-19 recovered patients. Hence, the above-mentioned factors have significantly affected the market.
MARKET PLAYERS
The report covers key developments in the HDAC inhibitor market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies activities witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for the expansion of business and customer base of market players. The market players from HDAC inhibitor market are anticipated to have lucrative growth opportunities in the future with the rising demand for HDAC inhibitor in the global market.
The report also includes the profiles of key companies along with their SWOT analysis and market strategies in the HDAC inhibitor market. In addition, the report focuses on leading industry players with information such as company profiles, components, and services offered, financial information of the last 3 years, the key development in the past five years.
-Celleron Therapeutics
-Celgene Corporation
-Novartis
-Eisai Co., Ltd
-Merck & Co., Inc.
-Pfizer Inc.
-Acetylon Pharmaceuticals, Inc.
-AstraZeneca plc.
-Chipscreen Biosciences
-Chroma Therapeutics
The Insight Partner's dedicated research and analysis team consist of experienced professionals with advanced statistical expertise and offer various customization options in the existing study.